ArticleThoracic cancer2026
Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transforming routine solid tumor profiling with automated next-generation sequencing: experience from a reference general hospital.Virchows Archiv : an international journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor advanced non-small cell lung cancer (NSCLC), biomarker testing using multiplex companion diagnostics has become the standard of care. However, challenges remain in detecting rare mutations and resistance mechanisms after targeted therapy. We evaluated the prevalence of druggable genetic aberrations and the clinical utility of comprehensive genomic profiling (CGP) performed after completion of standard treatment in real-world practice.
methodsThis retrospective study analyzed 108 patients with advanced or recurrent non-small cell lung cancer who underwent comprehensive genomic profiling testing between January 2019 and December 2023 at the Kanagawa Cancer Center Hospital, Japan. Profiling was conducted using the OncoGuide NCC Oncopanel System, FoundationOne, and FoundationOne Liquid companion diagnostics.
resultsDruggable genetic aberrations were detected in 37% of the patients, with epidermal growth factor receptor mutations being the most common. Resistance mechanisms were identified in 9 of 19 patients who underwent re-biopsy after targeted therapy. Non-smokers had a significantly higher rate of druggable mutations (55.6%) than did smokers (27.8%). Treatment based on comprehensive genomic profiling findings was recommended for 35.2% of the patients; however, only 16.6% received the suggested therapy. In a landmark survival analysis, patients who received genomically matched therapy demonstrated a trend toward prolonged overall survival compared with those who did not (log-rank p = 0.054).
conclusionsCGP testing can identify actionable mutations missed by conventional diagnostics and may provide additional therapeutic opportunities in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.